Search research articles
Contact Us
Filters
Showing results (41-50 of 171) with videos related to
Page
of 18
Sort By:
Breast Care (Basel, Switzerland)
|
May 4, 2012
ABC1 Consensus Conference - a German Perspective: First International Consensus Conference on Advanced Breast Cancer (ABC1), Lisbon, November 5, 2011
Christoph Thomssen, Norbert Marschner, Michael Untch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2017
Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Sabine Riethdorf, Volkmar Müller, Sibylle Loibl, et al.
Blood and Lymphatic Cancer : Targets and Therapy
|
June 10, 2025
An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma
Luciano J Costa, Thomas W LeBlanc, Hans Tesch, et al.
Breast (Edinburgh, Scotland)
|
February 29, 2024
Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy
David Krug, Valentina Vladimirova, Michael Untch, et al.
Breast (Edinburgh, Scotland)
|
January 14, 2026
Standardized patient coaching improves therapy persistence in patients with hormone receptor-positive, HER2-negative advanced/metastatic breast cancer treated with abemaciclib
Manfred Welslau, Peter A Fasching, Nicole Semmler-Lins, et al.
Annals of Hematology
|
October 4, 2023
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial
Steffen Koschmieder, Susanne Isfort, Clemens Schulte, et al.
Breast Care (Basel, Switzerland)
|
May 8, 2014
Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective
Nadia Harbeck, Norbert Marschner, Michael Untch, et al.
International Journal of Cancer
|
March 6, 2024
Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study
Diana Lüftner, Florian Schuetz, Andreas Schneeweiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2010
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial
Sabine Riethdorf, Volkmar Müller, Liling Zhang, et al.
European Journal of Haematology
|
July 7, 2025
Final Results From a Large, Non-Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine
Steffen Koschmieder, Susanne Isfort, Clemens Schulte, et al.
Page
of 18
Search research articles
Search
Showing results (41-50 of 171) with videos related to
Sort By:
Page
of 18
Breast Care (Basel, Switzerland)
|
May 4, 2012
ABC1 Consensus Conference - a German Perspective: First International Consensus Conference on Advanced Breast Cancer (ABC1), Lisbon, November 5, 2011
Christoph Thomssen, Norbert Marschner, Michael Untch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2017
Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Sabine Riethdorf, Volkmar Müller, Sibylle Loibl, et al.
Blood and Lymphatic Cancer : Targets and Therapy
|
June 10, 2025
An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma
Luciano J Costa, Thomas W LeBlanc, Hans Tesch, et al.
Breast (Edinburgh, Scotland)
|
February 29, 2024
Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy
David Krug, Valentina Vladimirova, Michael Untch, et al.
Breast (Edinburgh, Scotland)
|
January 14, 2026
Standardized patient coaching improves therapy persistence in patients with hormone receptor-positive, HER2-negative advanced/metastatic breast cancer treated with abemaciclib
Manfred Welslau, Peter A Fasching, Nicole Semmler-Lins, et al.
Annals of Hematology
|
October 4, 2023
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial
Steffen Koschmieder, Susanne Isfort, Clemens Schulte, et al.
Breast Care (Basel, Switzerland)
|
May 8, 2014
Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective
Nadia Harbeck, Norbert Marschner, Michael Untch, et al.
International Journal of Cancer
|
March 6, 2024
Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study
Diana Lüftner, Florian Schuetz, Andreas Schneeweiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2010
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial
Sabine Riethdorf, Volkmar Müller, Liling Zhang, et al.
European Journal of Haematology
|
July 7, 2025
Final Results From a Large, Non-Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine
Steffen Koschmieder, Susanne Isfort, Clemens Schulte, et al.
Page
of 18